The most advanced subunit malaria vaccine to date, RTS,S, is currently tested in a phase III clinical trial (NCT00866619) and is based on a fusion protein of part of the CSP of P. falciparum clone 3D7 (amino acids 207 – 395) with the hepatitis B surface antigen [34]. The gene discussed is DNAJC5; the disease is malaria.